Company

Boehringer Ingelheim Clinical trial approval / initiation

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD

Boehringer Ingelheim announced the initiation of the AIRWARD Phase III clinical study, evaluating verducatib, an investigational oral dipeptidyl peptidase‑1 (DPP1) inhibitor, in adult patients with chronic obstructive pulmonary disease (COPD)…

November 4, 2026

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications

November 3, 2026

Lifetech Scientific Wins CE MDR Certification for IBS Absorbable Drug‑Eluting Coronary Stent – World’s First Iron‑Based Bioresorbable Coronary Stent Approved

November 3, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Eli Lilly Haisco Pharmaceutical

Haisco Pharmaceutical and Eli Lilly Forge $3 Billion Drug Discovery Alliance Spanning Multiple Therapeutic Areas

June 2, 2026

BMS Bristol-Myers Squibb

BMS Secures EC Approval for Opdivo-AVD Combination in Advanced Classical Hodgkin Lymphoma